← Evidence map

ReviewBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2026

Why Product Drift Is Not an Issue for Biosimilars/Biologics: Start the Same, Stay the Same.

Joseph P Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Full record →Abstract, authors, funding and every citing paper · PMID 42420657